BR112021024856A2 - Amidas pirazolo-piridina substituídas e seu uso como moduladores do receptor de glun2b - Google Patents
Amidas pirazolo-piridina substituídas e seu uso como moduladores do receptor de glun2bInfo
- Publication number
- BR112021024856A2 BR112021024856A2 BR112021024856A BR112021024856A BR112021024856A2 BR 112021024856 A2 BR112021024856 A2 BR 112021024856A2 BR 112021024856 A BR112021024856 A BR 112021024856A BR 112021024856 A BR112021024856 A BR 112021024856A BR 112021024856 A2 BR112021024856 A2 BR 112021024856A2
- Authority
- BR
- Brazil
- Prior art keywords
- substituted pyrazolo
- glun2b receptor
- receptor modulators
- glun2b
- pyridine amides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
amidas pirazolo-piridina substituídas e seu uso como moduladores do receptor de glun2b. pirazolo-piridinas substituídas como ligantes do receptor glun2b. estes compostos podem ser usados na modulação do receptor de glun2b e em composições farmacêuticas e métodos para o tratamento de estados doentios, distúrbios e condições mediadas pela atividade do receptor de glun2b.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962861656P | 2019-06-14 | 2019-06-14 | |
PK35020 | 2020-06-03 | ||
ARP200101623A AR119125A1 (es) | 2019-06-14 | 2020-06-09 | Amidas de pirazolo-piridina sustituidas y su uso como moduladores del receptor glun2b |
PCT/EP2020/066392 WO2020249792A1 (en) | 2019-06-14 | 2020-06-12 | Substituted pyrazolo-pyridine amides and their use as glun2b receptor modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112021024856A2 true BR112021024856A2 (pt) | 2022-01-18 |
Family
ID=73781829
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112021024856A BR112021024856A2 (pt) | 2019-06-14 | 2020-06-12 | Amidas pirazolo-piridina substituídas e seu uso como moduladores do receptor de glun2b |
Country Status (21)
Country | Link |
---|---|
US (2) | US11618750B2 (pt) |
EP (1) | EP3983075A1 (pt) |
JP (1) | JP2022536522A (pt) |
KR (1) | KR20220024511A (pt) |
CN (1) | CN113993868A (pt) |
AU (1) | AU2020290016A1 (pt) |
BR (1) | BR112021024856A2 (pt) |
CA (1) | CA3142996A1 (pt) |
CL (1) | CL2021003277A1 (pt) |
CO (1) | CO2021016003A2 (pt) |
CR (1) | CR20210580A (pt) |
DO (1) | DOP2021000251A (pt) |
EC (1) | ECSP21090478A (pt) |
IL (1) | IL288859A (pt) |
JO (1) | JOP20210328A1 (pt) |
MA (1) | MA56196A (pt) |
MX (1) | MX2021015506A (pt) |
PE (1) | PE20220386A1 (pt) |
SG (1) | SG11202112407PA (pt) |
TW (1) | TW202112774A (pt) |
WO (1) | WO2020249792A1 (pt) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201819376A (zh) | 2016-10-06 | 2018-06-01 | 比利時商健生藥品公司 | 經取代之1H-咪唑並[4,5-b]吡啶-2(3H)-酮及其作為GLUN2B受體調節劑之用途 |
PE20220386A1 (es) | 2019-06-14 | 2022-03-18 | Janssen Pharmaceutica Nv | Amidas de pirazolo-piridina sustituidas y su uso como moduladores del receptor glun2b |
AU2020291188A1 (en) | 2019-06-14 | 2022-01-20 | Janssen Pharmaceutica Nv | Substituted heteroaromatic Pyrazolo-pyridines and their use as GluN2B receptor modulators |
AU2020293642A1 (en) | 2019-06-14 | 2022-01-20 | Janssen Pharmaceutica Nv | Substituted pyrazolo[4,3-b]pyridines and their use as GluN2B receptor modulators |
JP2022538795A (ja) | 2019-06-14 | 2022-09-06 | ヤンセン ファーマシューティカ エヌ.ベー. | ピラジンカルバメート及びGluN2B受容体調節因子としての使用 |
WO2020249799A1 (en) | 2019-06-14 | 2020-12-17 | Janssen Pharmaceutica Nv | Pyridine carbamates and their use as glun2b receptor modulators |
CA3143105A1 (en) | 2019-06-14 | 2020-12-17 | Janssen Pharmaceutica Nv | Substituted pyrazolo-pyrazines and their use as glun2b receptor modulators |
Family Cites Families (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9407447D0 (en) | 1994-04-14 | 1994-06-08 | Glaxo Group Ltd | Chemical compounds |
US6251897B1 (en) | 1996-07-31 | 2001-06-26 | Nikken Chemicals Co., Ltd | 6-phenyltetrahydro-1,3-oxazin-2-one derivative and pharmaceutical composition containing the same |
AU2001270149A1 (en) | 2000-06-26 | 2002-01-08 | Merck & Co., Inc. | Iminopyrimidine nmda nr2b receptor antagonists |
US6610723B2 (en) | 2001-01-29 | 2003-08-26 | Hoffmann-La Roche Inc. | Imidazole derivatives |
EP1490364B1 (en) | 2002-03-28 | 2007-09-26 | Eisai R&D Management Co., Ltd. | 7-azaindoles as inhibitors of c-jun n-terminal kinases for the treatment of neurodegenerative disorders |
US7005432B2 (en) | 2002-05-16 | 2006-02-28 | Hoffman-La Roche Inc. | Substituted imidazol-pyridazine derivatives |
KR20050004214A (ko) | 2002-05-31 | 2005-01-12 | 에자이 가부시키가이샤 | 피라졸 화합물 및 이것을 포함하여 이루어지는 의약 조성물 |
KR20070027503A (ko) | 2004-02-18 | 2007-03-09 | 아스트라제네카 아베 | 트리아졸 화합물 및 대사성 글루타메이트 수용체길항제로서 이들의 용도 |
AU2005286593A1 (en) | 2004-09-23 | 2006-03-30 | Reddy Us Therapeutics, Inc. | Novel pyridine compounds, process for their preparation and compositions containing them |
WO2007115231A2 (en) | 2006-03-30 | 2007-10-11 | Chemocentryx, Inc. | Cxcr4 modulators |
PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
AU2008257559B2 (en) | 2007-05-25 | 2013-10-10 | AbbVie Deutschland GmbH & Co. KG | Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (MGLU2 receptor) |
WO2009004430A1 (en) | 2007-06-29 | 2009-01-08 | Pfizer Inc. | N-benzyl oxazolidinones and related heterocycleic compounds as potentiators of glutamate receptors |
WO2009028543A1 (ja) | 2007-08-30 | 2009-03-05 | Takeda Pharmaceutical Company Limited | 置換ピラゾール誘導体 |
EP2215073A4 (en) | 2007-10-31 | 2011-04-06 | Merck Sharp & Dohme | SLEEP MODULATION WITH NR2B RECEPTOR ANTAGONISTS |
NZ588698A (en) | 2008-03-27 | 2012-06-29 | Evotec Neurosciences Gmbh | Methods for treating disorders using nmda nr2b-subtype selective antagonist |
WO2009157196A1 (ja) | 2008-06-25 | 2009-12-30 | 武田薬品工業株式会社 | アミド化合物 |
AU2009278442B2 (en) | 2008-08-05 | 2013-09-26 | Daiichi Sankyo Company, Limited | Imidazopyridin-2-one Derivatives |
US9643922B2 (en) | 2008-08-18 | 2017-05-09 | Yale University | MIF modulators |
EP2346505B1 (en) | 2008-10-16 | 2014-04-23 | Janssen Pharmaceuticals, Inc. | Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors |
EP2379561B1 (en) | 2008-11-25 | 2015-11-04 | University Of Rochester | Mlk inhibitors and methods of use |
WO2010108187A2 (en) | 2009-03-20 | 2010-09-23 | Brandeis University | Compounds and methods for treating mammalian gastrointestinal microbial infections |
WO2011022348A1 (en) | 2009-08-18 | 2011-02-24 | Janssen Pharmaceutica Nv | Ethylene diamine modulators of fatty acid amide hydrolase |
EP2579717A4 (en) | 2010-06-09 | 2013-12-11 | Merck Sharp & Dohme | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 |
US9212139B2 (en) * | 2010-06-16 | 2015-12-15 | Purdue Pharma, L.P. | Aryl substituted indoles and their use as blockers of sodium channels |
DK2669270T3 (en) * | 2011-01-28 | 2018-02-26 | Sato Pharma | Indole-related compounds such as URAT1 inhibitors |
JP2012188363A (ja) | 2011-03-09 | 2012-10-04 | Dainippon Sumitomo Pharma Co Ltd | アザベンゾイミダゾロン誘導体 |
DK2570415T3 (en) | 2011-09-19 | 2015-11-23 | Sanofi Sa | N- [4- (1H-pyrazolo [3,4-b] pyrazin-6-yl) phenyl] sulfonamides and their use as medicaments |
WO2013060029A1 (en) | 2011-10-28 | 2013-05-02 | Merck Sharp & Dohme Corp | Allosteric modulators of metabotropic glutamate receptors |
US9434743B2 (en) | 2012-03-02 | 2016-09-06 | Takeda Pharmaceutical Company Limited | Indazole derivatives |
MA37975B2 (fr) | 2012-09-11 | 2021-03-31 | Genzyme Corp | Inhibiteurs de synthase de glucosylcéramide |
WO2014124651A1 (en) | 2013-02-15 | 2014-08-21 | Københavns Universitet | Pyrrolidine-2-carboxylic acid derivatives as iglur antagonists |
US9650358B2 (en) | 2013-03-13 | 2017-05-16 | Abbvie Inc. | Pyridine CDK9 kinase inhibitors |
LT2970265T (lt) | 2013-03-15 | 2018-09-25 | Plexxikon Inc. | Heterocikliniai junginiai ir jų panaudojimas |
PL3010503T3 (pl) | 2013-06-21 | 2020-08-24 | Zenith Epigenetics Ltd. | Nowe bicykliczne inhibitory bromodomen |
CA2918242C (en) | 2013-07-31 | 2022-06-21 | Merck Patent Gmbh | Pyridines, pyrimidines, and pyrazines, as btk inhibitors and uses thereof |
USRE49517E1 (en) | 2014-08-15 | 2023-05-02 | Janssen Pharmaceuticals, Inc. | Pyrazoles |
PL3180329T3 (pl) | 2014-08-15 | 2020-08-24 | Janssen Pharmaceuticals, Inc. | Triazole jako inhibitory receptora NR2B |
US20170313719A1 (en) | 2014-11-18 | 2017-11-02 | Emory University | Thieno[2,3-D]pyrimidin-4-one Derivatives as NMDAR Modulators and Uses Related Thereto |
MA41803A (fr) | 2015-03-24 | 2018-01-30 | Almirall Sa | Dérivés amino-indazoles utilisés comme inhibiteurs des canaux sodiques |
MD3319963T2 (ro) | 2015-07-09 | 2020-05-31 | Janssen Pharmaceutica Nv | 4-Azaindoli substituiți și utilizarea lor în calitate de modulatori ai receptorului GluN2B |
SG11201806750WA (en) | 2016-02-10 | 2018-09-27 | Janssen Pharmaceutica Nv | Substituted 1,2,3-triazoles as nr2b-selective nmda modulators |
TW201819376A (zh) | 2016-10-06 | 2018-06-01 | 比利時商健生藥品公司 | 經取代之1H-咪唑並[4,5-b]吡啶-2(3H)-酮及其作為GLUN2B受體調節劑之用途 |
BR112019026478A2 (pt) | 2017-06-14 | 2020-07-14 | Trevena, Inc. | compostos para modulação da atividade de s1p1 e métodos de uso dos mesmos |
US10766893B2 (en) | 2017-12-20 | 2020-09-08 | H. Lundbeck A/S | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors |
EP3774732A4 (en) | 2018-04-04 | 2022-02-09 | Janssen Pharmaceutica NV | PYRIDINE AND SUBSTITUTED PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS |
CN110294756A (zh) | 2019-06-04 | 2019-10-01 | 广州市原子高科同位素医药有限公司 | GluN2B亚基靶向型中枢神经系统正电子示踪剂及其制备 |
AU2020293642A1 (en) | 2019-06-14 | 2022-01-20 | Janssen Pharmaceutica Nv | Substituted pyrazolo[4,3-b]pyridines and their use as GluN2B receptor modulators |
AU2020291188A1 (en) | 2019-06-14 | 2022-01-20 | Janssen Pharmaceutica Nv | Substituted heteroaromatic Pyrazolo-pyridines and their use as GluN2B receptor modulators |
WO2020249799A1 (en) | 2019-06-14 | 2020-12-17 | Janssen Pharmaceutica Nv | Pyridine carbamates and their use as glun2b receptor modulators |
JP2022538795A (ja) | 2019-06-14 | 2022-09-06 | ヤンセン ファーマシューティカ エヌ.ベー. | ピラジンカルバメート及びGluN2B受容体調節因子としての使用 |
CA3143105A1 (en) | 2019-06-14 | 2020-12-17 | Janssen Pharmaceutica Nv | Substituted pyrazolo-pyrazines and their use as glun2b receptor modulators |
PE20220386A1 (es) | 2019-06-14 | 2022-03-18 | Janssen Pharmaceutica Nv | Amidas de pirazolo-piridina sustituidas y su uso como moduladores del receptor glun2b |
-
2020
- 2020-06-12 PE PE2021001941A patent/PE20220386A1/es unknown
- 2020-06-12 SG SG11202112407PA patent/SG11202112407PA/en unknown
- 2020-06-12 BR BR112021024856A patent/BR112021024856A2/pt unknown
- 2020-06-12 US US16/899,823 patent/US11618750B2/en active Active
- 2020-06-12 MA MA056196A patent/MA56196A/fr unknown
- 2020-06-12 KR KR1020227001089A patent/KR20220024511A/ko unknown
- 2020-06-12 CA CA3142996A patent/CA3142996A1/en active Pending
- 2020-06-12 CN CN202080043675.8A patent/CN113993868A/zh active Pending
- 2020-06-12 WO PCT/EP2020/066392 patent/WO2020249792A1/en unknown
- 2020-06-12 CR CR20210580A patent/CR20210580A/es unknown
- 2020-06-12 JP JP2021573898A patent/JP2022536522A/ja active Pending
- 2020-06-12 AU AU2020290016A patent/AU2020290016A1/en active Pending
- 2020-06-12 TW TW109119835A patent/TW202112774A/zh unknown
- 2020-06-12 EP EP20737362.2A patent/EP3983075A1/en active Pending
- 2020-06-12 MX MX2021015506A patent/MX2021015506A/es unknown
- 2020-06-12 JO JOP/2021/0328A patent/JOP20210328A1/ar unknown
-
2021
- 2021-11-26 CO CONC2021/0016003A patent/CO2021016003A2/es unknown
- 2021-12-02 DO DO2021000251A patent/DOP2021000251A/es unknown
- 2021-12-09 CL CL2021003277A patent/CL2021003277A1/es unknown
- 2021-12-09 IL IL288859A patent/IL288859A/en unknown
- 2021-12-14 EC ECSENADI202190478A patent/ECSP21090478A/es unknown
-
2022
- 2022-10-14 US US17/966,696 patent/US20230151006A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
DOP2021000251A (es) | 2022-04-18 |
US11618750B2 (en) | 2023-04-04 |
KR20220024511A (ko) | 2022-03-03 |
US20210017168A1 (en) | 2021-01-21 |
TW202112774A (zh) | 2021-04-01 |
EP3983075A1 (en) | 2022-04-20 |
CA3142996A1 (en) | 2020-12-17 |
JP2022536522A (ja) | 2022-08-17 |
CL2021003277A1 (es) | 2022-08-19 |
ECSP21090478A (es) | 2022-01-31 |
CO2021016003A2 (es) | 2021-12-10 |
JOP20210328A1 (ar) | 2023-01-30 |
CR20210580A (es) | 2022-01-31 |
MX2021015506A (es) | 2022-02-10 |
MA56196A (fr) | 2022-04-20 |
AU2020290016A1 (en) | 2022-01-06 |
IL288859A (en) | 2022-02-01 |
PE20220386A1 (es) | 2022-03-18 |
WO2020249792A1 (en) | 2020-12-17 |
SG11202112407PA (en) | 2021-12-30 |
US20230151006A1 (en) | 2023-05-18 |
CN113993868A (zh) | 2022-01-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112021024856A2 (pt) | Amidas pirazolo-piridina substituídas e seu uso como moduladores do receptor de glun2b | |
BR112018000468A2 (pt) | 4-azaindóis substituídos e seu uso como moduladores do receptor de glun2b | |
BR112021025141A2 (pt) | Pirazolo-piridinas heteroaromáticas substituídas e seu uso como moduladores do receptor glun2b | |
BR112021024117A2 (pt) | Pirazolo-pirazinas substituídas e seu uso como moduladores do receptor de glun2b | |
BR112019006691A2 (pt) | 1h-imidazo[4,5-b]piridin-2(3h)-onas substituídas e seu uso como moduladores do receptor de glun2b | |
CO2021007993A2 (es) | Compuestos de 2‐formil‐3‐hidroxifeniloximetilo capaces de modular la hemoglobina | |
BR112018016329A2 (pt) | 1,2,3-triazóis substituídos como moduladores de nmda seletivos para nr2b | |
BR112021025136A2 (pt) | Pirazolo[4,3-b]piridinas substituídas e seu uso como moduladoras do receptor de glun2b | |
EA201890725A1 (ru) | Агонисты фарнезоидного х-рецептора и их применение | |
BR112017011972A2 (pt) | derivados de azabicicloctano como agonistas de fxr para uso no tratamento de doenças hepáticas e gastrintestinais | |
BR112015018092A2 (pt) | moduladores de receptor de nmda de espiro-lactama e usos dos mesmos | |
EA201791007A3 (ru) | Соединения и их применения для модуляции гемоглобина | |
BR112015018094A2 (pt) | moduladores de receptor nmda de espiro-lactama e usos dos mesmos | |
EA201591426A1 (ru) | Соединения и их применения для модуляции гемоглобина | |
BR112015018087A2 (pt) | moduladores de receptor nmda de espiro-lactama e usos dos mesmos | |
CL2015002546A1 (es) | Derivados 3-fenilpropilamina sustituidos para el tratamiento de enfermedades y trastornos oftálmicos | |
BR112015018089A2 (pt) | moduladores de receptor de nmda de espiro-lactama e usos dos mesmos | |
EA201591432A1 (ru) | Соединения и их применения для модуляции гемоглобина | |
CO2019010078A2 (es) | Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1 | |
EA201992083A1 (ru) | Модуляторы соматостатина и их применения | |
BR112021025132A2 (pt) | Carbamatos de piridina e seu uso como moduladores do receptor glun2b | |
EA201990425A1 (ru) | Спиролактамовые и бис-спиролактамовые модуляторы nmda-рецептора и их применение | |
BR112014011333A2 (pt) | derivados de pregenen-11ss-17-21-triol-3,20-diona para o tratamento de condições oculares | |
CO2017012622A2 (es) | Moduladores alostéricos positivos del receptor muscarínico m2 | |
MX2021015511A (es) | Carbamatos de pirazina y sus usos como moduladores del receptor glun2b. |